Fibroblast growth factor 21 is an early predictor of acute‐on‐chronic liver failure in critically ill patients with cirrhosis

Astrid Ruiz‐Margáin, Alessandra Pohlmann, Patrick Ryan, Robert Schierwagen, Luis A. Chi‐Cervera, Christian Jansen, Osvely Mendez‐Guerrero, Nayelli C. Flores‐García, Jennifer Lehmann, Aldo Torre, Ricardo Ulises Macías‐Rodríguez, Jonel Trebicka – 24 February 2018 – Acute‐on‐chronic liver failure (ACLF) develops in acute decompensation (AD) of cirrhosis and shows high mortality. In critically ill patients, early diagnosis of ACLF could be important for therapeutic decisions (eg, renal replacement, artificial liver support, liver transplantation).

Direct‐acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local‐regional therapy or liver transplant waitlist dropout

Annsa C. Huang, Neil Mehta, Jennifer L. Dodge, Francis Y. Yao, Norah A. Terrault – 24 February 2018 – Whether direct‐acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC) recurrence after tumor‐directed therapy is controversial. We sought to determine the impact of DAA therapy on HCC recurrence after local‐regional therapy (LRT) and waitlist dropout among liver transplant (LT) candidates with HCC. We performed a retrospective cohort study of 149 LT candidates with hepatitis C virus (HCV) and HCC at a single center from 2014 through 2016.

Cold ischemia time is an important risk factor for post–liver transplant prolonged length of stay

Evelyn T. Pan, Dor Yoeli, N. Thao N. Galvan, Michael L. Kueht, Ronald T. Cotton, Christine A. O'Mahony, John A. Goss, Abbas Rana – 24 February 2018 – Risk analysis of cold ischemia time (CIT) in liver transplantation has largely focused on patient and graft survival. Posttransplant length of stay is a sensitive marker of morbidity and cost. We hypothesize that CIT is a risk factor for posttransplant prolonged length of stay (PLOS) and aim to conduct an hour‐by‐hour analysis of CIT and PLOS.

Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial

Graham R. Foster, Kosh Agarwal, Matthew E. Cramp, Sulleman Moreea, Stephen Barclay, Jane Collier, Ashley S. Brown, Stephen D. Ryder, Andrew Ustianowski, Daniel M. Forton, Ray Fox, Fiona Gordon, William M. Rosenberg, David J. Mutimer, Jiejun Du, Christopher L. Gilbert, Ernest Asante‐Appiah, Janice Wahl, Michael N. Robertson, Eliav Barr, Barbara Haber – 23 February 2018 – Many direct‐acting antiviral regimens have reduced activity in people with hepatitis C virus (HCV) genotype (GT) 3 infection and cirrhosis.

Subscribe to